RESUMEN
The hormone Erythroferrone (ERFE) is a member of the C1q/TNF-related protein family that regulates iron homeostasis through the suppression of hamp. In a gain of function screen in Xenopus embryos, we identified ERFE as a potent secondary axis-inducing agent. Experiments in Xenopus embryos and ectodermal explants revealed that ERFE functions as a selective inhibitor of the BMP pathway and the conserved C1q domain is not required for this activity. Inhibition occurs at the extracelluar level, through the interaction of ERFE with the BMP ligand. During early Xenopus embryogenesis, erfe is first expressed in the ventral blood islands where initial erythropoiesis occurs and later in circulating blood cells. ERFE knockdown does not alter the expression of etv.2, aplnr and flt1 in tailbud stage embryos indicating endothelial cell specification is independent of ERFE. However, in tadpole embryos, defects of the vascular network and primitive blood circulation are observed as well as edema formation. RNAseq analysis of ERFE morphant embryos also revealed the inhibition of gja4 indicating disruption of dorsal aorta formation.
Asunto(s)
Proteína Morfogenética Ósea 4/metabolismo , Sistema Cardiovascular/embriología , Colágeno/metabolismo , Citocinas/metabolismo , Proteínas Musculares/metabolismo , Hormonas Peptídicas/metabolismo , Proteínas de Xenopus/metabolismo , Animales , Colágeno/genética , Citocinas/genética , Ectodermo/metabolismo , Desarrollo Embrionario/genética , Eritrocitos/metabolismo , Eritropoyesis/genética , Femenino , Técnicas de Silenciamiento del Gen , Masculino , Proteínas Musculares/genética , Hormonas Peptídicas/genética , RNA-Seq , Transducción de Señal/genética , Proteínas de Xenopus/genética , Xenopus laevisRESUMEN
In humans, many cases of congenital insensitivity to pain (CIP) are caused by mutations of components of the NGF/TrkA signaling pathway, which is required for survival and specification of nociceptors and plays a major role in pain processing. Mutations in PRDM12 have been identified in CIP patients that indicate a putative role for this transcriptional regulator in pain sensing. Here, we show that Prdm12 expression is restricted to developing and adult nociceptors and that its genetic ablation compromises their viability and maturation. Mechanistically, we find that Prdm12 is required for the initiation and maintenance of the expression of TrkA by acting as a modulator of Neurogenin1/2 transcription factor activity, in frogs, mice, and humans. Altogether, our results identify Prdm12 as an evolutionarily conserved key regulator of nociceptor specification and as an actionable target for new pain therapeutics.